Establishment Labs Shares Surge Premarket on FDA Breast Implant Approval
Provided by
Dow Jones
By Colin Kellaher
Establishment Labs Holdings shares jumped nearly 30% in premarket trading Friday after the medical-technology company won Food and Drug Administration approval for its Motiva breast implants.
After the closing bell Thursday, Establishment Labs said the FDA cleared the use of its Motiva SmoothSilk Ergonomix and SmoothSilk Round implants in primary and revision breast augmentation.
Shares of the Costa Rica-based company, which closed Thursday at $41.20, were recently up 29% to $52.78 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2024 06:33 ET (10:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States